Yes. As of September 2026, STERIS plc (STE) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 8.59% / 30% · (Cash+Inv) / Mkt Cap (36m) 2.41% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 8.59% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 2.41% / 33% · Receivables / Mkt Cap (36m) 4.56% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 8.59% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 2.41% / 33.33% · Receivables / Mkt Cap (24m) 4.56% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 17.9% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 4.39% / 33.33% · Receivables / Avg Assets (4Q) 9.59% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 17.7% / 33.33% · (Cash+ST Inv) / Total Assets 4.96% / 33.33% · (Cash+Recv) / Total Assets 14.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
Yes. As of September 2026, STERIS plc (STE) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. STERIS plc is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
STERIS plc reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q2 2027). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
STERIS plc (NYSE: STE) is a Healthcare company (Medical - Specialties) with a market capitalization of $25.4B. The Maz Rating grades it against the other companies in its sector.
STERIS plc's current Maz Rating and its five factor grades are for members: log in to see them.
At $261.91, STERIS plc trades at 31.0x trailing earnings, 4.1x sales and 3.5x book value, with an EV/EBITDA of 17.5. Over the last twelve months it generated about $6.2B of revenue and $821M of net income. It runs a gross margin of 44.6%, an operating margin of 18.9% and a net margin of 13.4%. It shows return on equity of 11.5%, return on invested capital of 8.8% and a free cash flow yield of 3.7%. On the balance sheet: a debt-to-equity ratio of 0.28 and a current ratio of 2.05. Over the past 52 weeks the share price ranged from $195.14 to $269.44, with a beta of 0.86.
STERIS plc pays a dividend yielding 1.01%, with 30% of earnings paid out. Its Maz Dividend Score is 4.30 out of 5, ranked against the other dividend payers in its sector (Safety 3.03, Growth 4.43, Yield 2.83, Consistency 4.08).
14 Wall Street analyst ratings cover the stock: 12 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. The company operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. It offers a range of products including cleaning chemistries, sterility assurance products, automated endoscope reprocessing systems, surgical tables, lights, and connectivity solutions. It also provides services such as equipment maintenance, instrument repair, and contract sterilization for medical device and pharmaceutical manufacturers.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.